New thiouracil derivatives as histone deacetylase inhibitors and apoptosis inducers: design, synthesis and anticancer evaluation

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Maj E, Papiernik D, Wietrzyk J. Antiangiogenic cancer treatment: the great discovery and greater complexity. Int. J. Oncol. 49(5), 1773–1784 (2016). • Cancer mechanisms and its biological target. These articles give a brief background about different mechanisms of cancer treatments. In addition, the variety of biological targets that involved in cancer treatment were discussed.
  Medline CASGoogle Scholar
• 2. El-Helby AGA, Sakr H, Eissa IH, Al-Karmalawy AA, El-Adl K. Benzoxazole/benzothiazole-derived VEGFR-2 inhibitors: design, synthesis, molecular docking, and anticancer evaluations. Arch. Pharm. 352(12), 1900178 (2019). •• Describe the design of new compounds and the essential pharmacophoric features. This includes the ligand-based and structural-based drug-design approaches. As well as, the computer aided drug discovery was clarified.
  CASGoogle Scholar
• 3. Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 17, 471–494 (2014).
  Medline CASGoogle Scholar
• 4. Alanazi MM, Elkady H, Alsaif NA et al. New quinoxaline-based VEGFR-2 inhibitors: design, synthesis, and antiproliferative evaluation with in silico docking, ADMET, toxicity, and DFT studies. RSC Adv. 11(48), 30315–30328 (2021).
  Medline CASGoogle Scholar
• 5. Deng B, Luo Q, Halim A, Liu Q, Zhang B, Song G. The antiangiogenesis role of histone deacetylase inhibitors: their potential application to tumor therapy and tissue repair. DNA Cell Biol. 39(2), 167–176 (2020).
  Medline CASGoogle Scholar
• 6. Ellis L, Hammers H, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett. 280(2), 145–153 (2009).
  Medline CASGoogle Scholar
• 7. Marson CM, Mahadevan T, Dines J et al. Structure–activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase. Bioorg. Med. Chem. Lett. 17(1), 136–141 (2007).
  Medline CASGoogle Scholar
• 8. Hassig CA, Schreiber SL. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr. Res. Chem. Biol. 1(3), 300–308 (1997).
  CASGoogle Scholar
• 9. Moradei O, Maroun CR, Paquin I, Vaisburg A. Histone deacetylase inhibitors: latest developments, trends and prospects. Curr. Med. Chem. Anticancer Agents 5(5), 529–560 (2005).
  Medline CASGoogle Scholar
• 10. Kim H-J, Bae S-C. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am. J. Transl. Res. 3(2), 166 (2011).
  Medline CASGoogle Scholar
• 11. Zhao C, Dong H, Xu Q, Zhang Y. Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017–present). Expert Opin. Ther. Pat. 30(4), 263–274 (2020).
  Medline CASGoogle Scholar
• 12. Bubna AK. Vorinostat – an overview. Indian J. Dermatol. 60(4), 419 (2015).
  MedlineGoogle Scholar
• 13. Connolly RM, Rudek MA, Piekarz R. Entinostat: a promising treatment option for patients with advanced breast cancer. Future Oncol. 13(13), 1137–1148 (2017). •• Histone deacetylase (HDAC) as promising anti-cancer target. HDACs are promising targets for cancer chemoprevention and chemotherapy depending on their involvement in gene expression and the variety of cellular functions involved in carcinogenesis, cell growth, survival and homologous recombination.
  Medline CASGoogle Scholar
• 14. Laubach JP, Moreau P, San-Miguel JF, Richardson PG. Panobinostat for the treatment of multiple myeloma. Clin. Cancer Res. 21(21), 4767–4773 (2015).
  Medline CASGoogle Scholar
• 15. Bruserud O, Stapnes C, Ersvaer E, Gjertsen B, Ryningen A. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cells. Curr. Pharm. Biotechnol. 8(6), 388–400 (2007).
  Medline CASGoogle Scholar
• 16. Awad SM, Zohny YM, Ali SA, Mahgoub S, Said AM. Design, synthesis, molecular modeling, and biological evaluation of novel thiouracil derivatives as potential antithyroid agents. Molecules 23(11), 2913 (2018). •• Describes the design of new compounds and the essential pharmacophoric features. Pharmacophoric features are necessary forgood design of new anticancer agents. The different pharmacophoric features were clarified as reported before.
  MedlineGoogle Scholar
• 17. El-Naggar AM, Abou-El-Regal MM, El-Metwally SA, Sherbiny FF, Eissa IH. Synthesis, characterization and molecular docking studies of thiouracil derivatives as potent thymidylate synthase inhibitors and potential anticancer agents. Mol. Divers. 21(4), 967–983 (2017).
  Medline CASGoogle Scholar
• 18. Li Y, Wang Y, Xie N et al. Design, synthesis and antiproliferative activities of novel benzamides derivatives as HDAC inhibitors. Eur. J. Med. Chem. 100, 270–276 (2015).
  Medline CASGoogle Scholar
• 19. El-Kalyoubi SA, Taher ES, Ibrahim TS, El-Behairy MF, Al-Mahmoudy AM. Uracil as a Zn-binding bioisostere of the allergic benzenesulfonamide in the design of quinoline–uracil hybrids as anticancer carbonic anhydrase inhibitors. Pharmaceuticals 15(5), 494 (2022).
  Medline CASGoogle Scholar
• 20. Han H, Li C, Li M et al. Design, synthesis, and biological evaluation of 8-mercapto-3,7-dihydro-1H-purine-2,6-diones as potent inhibitors of SIRT1, SIRT2, SIRT3, and SIRT5. Molecules 25(12), 2755 (2020).
  Medline CASGoogle Scholar
• 21. Chin TF, Wu WH, Lach JL. Comparative hydrolytic rates of N-substituted 6-amino-thiouracils. J. Pharm. Sci. 56(5), 562–565 (1967).
  Medline CASGoogle Scholar
• 22. El-Kalyoubi S, Agili F. Synthesis, in silico prediction and in vitro evaluation of antitumor activities of novel pyrido [2,3-d] pyrimidine, xanthine and lumazine derivatives. Molecules 25(21), 5205 (2020). •• Describes the chemical synthesis of new compounds. The optimal condition for the synthesis of new compounds were presented. In addition, the methods of characterizations were reported.
  Medline CASGoogle Scholar
• 23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65(1–2), 55–63 (1983). •• Describes the biological testing methods.
  Medline CASGoogle Scholar
• 24. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods 89(2), 271–277 (1986).
  Medline CASGoogle Scholar
• 25. Thabrew MI, Hughes RD, McFarlane IG. Screening of hepatoprotective plant components using a HepG2 cell cytotoxicity assay. J. Pharm. Pharmacol. 49(11), 1132–1135 (1997).
  Medline CASGoogle Scholar
• 26. Al-Rashood ST, Hamed AR, Hassan GS et al. Antitumor properties of certain spirooxindoles towards hepatocellular carcinoma endowed with antioxidant activity. J. Enzyme Inhib. Med. Chem. 35(1), 831–839 (2020).
  Medline CASGoogle Scholar
• 27. Fournel M, Bonfils C, Hou Y et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol. Cancer Ther. 7(4), 759–768 (2008).
  Medline CASGoogle Scholar
• 28. Eldehna WM, Hassan GS, Al-Rashood ST et al. Synthesis and in vitro anticancer activity of certain novel 1-(2-methyl-6-arylpyridin-3-yl)-3-phenylureas as apoptosis-inducing agents. J. Enzyme Inhib. Med. Chem. 34(1), 322–332 (2019).
  Medline CASGoogle Scholar
• 29. Yousef RG, Sakr HM, Eissa IH et al. New quinoxaline-2(1H)-ones as potential VEGFR-2 inhibitors: design, synthesis, molecular docking, ADMET profile and anti-proliferative evaluations. New J. Chem. 45(36), 16949–16964 (2021).
  CASGoogle Scholar
• 30. Lo KK-W, Lee TK-M, Lau JS-Y, Poon W-L, Cheng S-H. Luminescent biological probes derived from ruthenium (II) estradiol polypyridine complexes. Inorg. Chem. 47(1), 200–208 (2008).
  Medline CASGoogle Scholar
• 31. Elkady H, Elwan A, El-Mahdy HA et al. New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, anti-proliferative evaluation, flow cytometric analysis, and in silico studies. J. Enzyme Inhib. Med. Chem. 37(1), 403–416 (2022).
  CASGoogle Scholar
• 32. Balah A, Ezzat O, Akool E-S. Vitamin E inhibits cyclosporin A-induced CTGF and TIMP-1 expression by repressing ROS-mediated activation of TGF-β/Smad signaling pathway in rat liver. Int. Immunopharmacol. 65, 493–502 (2018).
  Medline CASGoogle Scholar
• 33. Aborehab NM, Elnagar MR, Waly NE. Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. J. Biochem. Mol. Toxicol. 35(2), e22638 (2020).
  MedlineGoogle Scholar
• 34. Elnagar MR, Walls AB, Helal GK, Hamada FM, Thomsen MS, Jensen AA. Functional characterization of α7 nicotinic acetylcholine and NMDA receptor signaling in SH-SY5Y neuroblastoma cells in an ERK phosphorylation assay. Eur. J. Pharmacol. 826, 106–113 (2018).
  Medline CASGoogle Scholar
• 35. Ma C, Taghour MS, Belal A et al. Design and synthesis of new quinoxaline derivatives as potential histone deacetylase inhibitors targeting hepatocellular carcinoma: in silico, in vitro, and SAR studies. Front. Chem. 9, 725135 (2021).
  Medline CASGoogle Scholar